Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deucravacitinib for the Treatment of Psoriatic Disease
Ana Maria Lé, L. Puig, Tiago Torres
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 6, pp. 813-822
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Deucravacitinib: First Approval
Sheridan M. Hoy
Drugs (2022) Vol. 82, Iss. 17, pp. 1671-1679
Open Access | Times Cited: 125
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study
Amita Datta‐Mannan, Arie Regev, David E. Coutant, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 5, pp. 1152-1161
Open Access | Times Cited: 12
Early and delayed STAT1-dependent responses drive local trained immunity of macrophages in the spleen
Aryeh Solomon, Noa Bossel Ben‐Moshe, Dotan Hoffman, et al.
eLife (2025) Vol. 13
Open Access | Times Cited: 1
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Fan Yang, Chaofan Lu, Yanhong Wang, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 6, pp. 1593-1605
Closed Access | Times Cited: 17
Deucravacitinib in the treatment of psoriasis
Tomás Estevinho, Ana Maria Lé, Tiago Torres
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 24
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 15
Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases
Tong Li, Xianjing Yang, Juan Zhu, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110660-110660
Closed Access | Times Cited: 13
Recent developments for new investigational JAK inhibitors in psoriatic arthritis
Francesco Caso, Luisa Costa, Paola Triggianese, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 361-371
Closed Access | Times Cited: 11
Pentraxin 3 exacerbates psoriasiform dermatitis through regulation of macrophage polarization
Jingwei Liu, Cheng Qiu, Zhonghua Zhou, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111805-111805
Closed Access | Times Cited: 4
Therapeutic Inhibition of the JAK-STAT pathway in the treatment of Inflammatory Bowel Disease.
Zihan Chen, Ping Jiang, Dan Su, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 1-15
Closed Access | Times Cited: 4
Early and Delayed STAT1-Dependent Responses Drive Local Trained Immunity of Macrophages in the Spleen
Aryeh Solomon, Noa Bossel Ben‐Moshe, Dotan Hoffman, et al.
(2025)
Open Access
An overview of small-molecule agents for the treatment of psoriasis
Zhiheng Jin, Gang Li, Dengqin He, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118067-118067
Closed Access
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis
Robin C. Yi, Maya Akbik, Logan R. Smith, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1312-1312
Open Access
American Academy of Dermatology Annual Meeting: Orlando, FL, USA, 7-11 March 2025
Kathy A Fraser
American Journal of Clinical Dermatology (2025)
Closed Access
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors
Kuojun Zhang, Ke Ye, He Tang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4378-4416
Closed Access | Times Cited: 10
Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
Nicole Bouché, Miriam Al-Saedy, Eingun James Song
JAAD Case Reports (2023) Vol. 39, pp. 93-95
Open Access | Times Cited: 10
Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis
Yuanyuan Xu, Z. Li, S. Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
Yi‐Ru Bai, Xin Yang, Ken Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116759-116759
Closed Access | Times Cited: 3
Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
Yujian Yang, Liu Cao, Ming Yan, et al.
Antiviral Research (2023) Vol. 213, pp. 105586-105586
Open Access | Times Cited: 7
Separation and characterization of hydrolytic degradation product of deucravacitinib by validated high‐performance liquid chromatography method and liquid chromatography‐mass spectrometry
Vijaya Madhyanapu Golla, Rahul Khemchandani, Sowmya Chaganti, et al.
Separation Science Plus (2024) Vol. 7, Iss. 5
Closed Access | Times Cited: 2
Updates in treatment and impact of nail psoriasis
Matilde Iorizzo, Antonellá Tosti
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1091-1100
Closed Access | Times Cited: 6
Progress on the Pharmacological Targeting of Janus Pseudokinases
Sean P. Henry, William L. Jorgensen
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10959-10990
Closed Access | Times Cited: 6
An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis
B. K. Soni, Riya Shivgotra, Karan Trehan, et al.
Current Drug Targets (2024) Vol. 25, Iss. 5, pp. 353-373
Closed Access | Times Cited: 2
Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
Ana María Martins, Ana Maria Lé, Tiago Torres
Drugs in Context (2023) Vol. 12, pp. 1-8
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top